These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 9456433)

  • 1. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.
    Cormier JN; Abati A; Fetsch P; Hijazi YM; Rosenberg SA; Marincola FM; Topalian SL
    J Immunother; 1998 Jan; 21(1):27-31. PubMed ID: 9456433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma.
    de Vries TJ; Trancikova D; Ruiter DJ; van Muijen GN
    Br J Cancer; 1998 Nov; 78(9):1156-61. PubMed ID: 9820172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
    Jäger E; Ringhoffer M; Karbach J; Arand M; Oesch F; Knuth A
    Int J Cancer; 1996 May; 66(4):470-6. PubMed ID: 8635862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.
    Marincola FM; Hijazi YM; Fetsch P; Salgaller ML; Rivoltini L; Cormier J; Simonis TB; Duray PH; Herlyn M; Kawakami Y; Rosenberg SA
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):192-205. PubMed ID: 8811494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
    Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
    J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
    Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
    Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
    Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
    J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of melanoma-associated antigens in melanoma cell cultures.
    Urosevic M; Braun B; Willers J; Burg G; Dummer R
    Exp Dermatol; 2005 Jul; 14(7):491-7. PubMed ID: 15946236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.
    Al-Batran SE; Rafiyan MR; Atmaca A; Neumann A; Karbach J; Bender A; Weidmann E; Altmannsberger HM; Knuth A; Jäger E
    Cancer Res; 2005 May; 65(9):3937-41. PubMed ID: 15867394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.
    Cormier JN; Hijazi YM; Abati A; Fetsch P; Bettinotti M; Steinberg SM; Rosenberg SA; Marincola FM
    Int J Cancer; 1998 Feb; 75(4):517-24. PubMed ID: 9466650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy.
    Trefzer U; Hofmann M; Reinke S; Guo YJ; Audring H; Spagnoli G; Sterry W
    Melanoma Res; 2006 Apr; 16(2):137-45. PubMed ID: 16567969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
    de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
    Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
    J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates.
    Griffioen M; Borghi M; Schrier PI; Osanto S; Schadendorf D
    Cancer Immunol Immunother; 2004 Aug; 53(8):715-22. PubMed ID: 14997347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of MART-1 in primary and metastatic melanoma lesions.
    Kageshita T; Kawakami Y; Hirai S; Ono T
    J Immunother; 1997 Nov; 20(6):460-5. PubMed ID: 9409451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies.
    Michaeli Y; Denkberg G; Sinik K; Lantzy L; Chih-Sheng C; Beauverd C; Ziv T; Romero P; Reiter Y
    J Immunol; 2009 May; 182(10):6328-41. PubMed ID: 19414786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
    de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
    J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
    Butterfield LH; Comin-Anduix B; Vujanovic L; Lee Y; Dissette VB; Yang JQ; Vu HT; Seja E; Oseguera DK; Potter DM; Glaspy JA; Economou JS; Ribas A
    J Immunother; 2008 Apr; 31(3):294-309. PubMed ID: 18317358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones.
    Kirkin AF; thor Straten P; Hansen MR; Barfoed A; Dzhandzhugazyan KN; Zeuthen J
    Cancer Immunol Immunother; 1999 Aug; 48(5):239-46. PubMed ID: 10478640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.